inCare – Finding eligible patients

A: A health system's own coded data already contains the answer, spread across diagnosis codes, treatment records and follow-up history that were never pulled together into one view. inCare brings that existing data together to show which diagnosed patients have profiles consistent with trial or therapy eligibility for clinician confirmation, as well as which of them have never started treatment, stopped early, been placed on the wrong therapy, or fallen out of follow-up.

A: Both work with patients a pharma team cannot yet reach, but the patients sit in different places. inCare works within a population that is already diagnosed and coded, finding people who are eligible for a therapy or trial but have gone untreated or lost from view. inTrigue reaches beyond the coded population altogether, finding patients who have never received the right diagnosis or code at all.

A: The two sit on either side of a clinical threshold. inAdvance works before that threshold is crossed, finding patients on a trajectory towards a diagnosis so intervention can happen earlier. inCare works after it, among patients already diagnosed, finding those eligible for a therapy who have gone untreated or lost from view.

A: No. inCare answers a question of access: is this diagnosed patient receiving the treatment they are eligible for, or are they untreated, on the wrong therapy, or lost from follow-up. Once that treatment gap is closed, inFlow answers a different question, forecasting how the patient is likely to respond to treatment, progress in their disease, or relapse.

A: Volv Global does not receive directly identifiable patient data. Volv Global works through trusted data partners operating under the privacy and regulatory frameworks that apply in each market, and follows rigorous validation processes to keep its methodology accurate and designed to reduce bias. inCare surfaces and groups eligible patients for clinical attention; it does not diagnose, prescribe, or replace clinical judgement.